Pfizer to buy cancer-drug maker Medivation for $14 billion
Pfizer’s $14 billion deal to buy San Francisco’s Medivation Inc. adds a blockbuster prostate-cancer drug to the pharmaceutical giant’s roster of drugs and strengthens its line of lucrative cancer therapies. Medivation’s CEO, Dr. David Hung, described Pfizer as the “ideal partner” to extend the reach of its prostate cancer drug, called Xtandi, as well...
I regard the brain as a computer which will stop working when its component fail. There is no heaven or afterlife for broken-down computers. That is a fairy story for people afraid of the dark